Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Oral Single and Multiple Ascending Doses, Parallel Group Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects
NCT05154240 is registered in ClinicalTrials.gov with InSilico Medicine Hong Kong Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Oral Single and Multiple Ascending Doses, Parallel Group Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects
- Lead sponsor
- InSilico Medicine Hong Kong Limited
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 21, 2022
- Completion date
- December 2, 2022
- Enrollment
- 78 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.